Eli Lilly and Co.

Related Articles

Cath Lab

Studies Show Effect of Prasugrel vs. Clopidogrel on Readmissions, Initial Hospitalization Costs in ACS-PCI Patients
Low Clopidogrel Responsiveness Predicts Stent Thrombosis, Heart Attack
TRILOGY ACS Shows Prasugrel Not Superior to Clopidogrel in Medically Managed Non-STEMI Patients Without Revascularization
New Data and Recent Advances in Antiplatelet Agents
Prasugrel Significantly Reduces Cardiovascular Events Over Clopidogrel
Switching PCI Patients to Prasugrel from Clopidogrel Reduces Max Platelet Aggregation
Daiichi Sankyo/Lilly Respond to Antiplatelet Clinical Alert

Antiplatelet Therapy

Studies Show Effect of Prasugrel vs. Clopidogrel on Readmissions, Initial Hospitalization Costs in ACS-PCI Patients
Low Clopidogrel Responsiveness Predicts Stent Thrombosis, Heart Attack
Tailored Therapy Using Clopidogrel is Superior to Prasugrel in Reducing High Platelet Reactivity
TRILOGY ACS Shows Prasugrel Not Superior to Clopidogrel in Medically Managed Non-STEMI Patients Without Revascularization
New Data and Recent Advances in Antiplatelet Agents
New Analysis of Data Presented at AHA: Prasugrel’s Effect on Cardiovascular Events in STEMI Patients According to Timing of PCI
Prasugrel Significantly Reduces Cardiovascular Events Over Clopidogrel
Prasugrel Added to Updated ACCF/AHA Guidelines for ACS-PCI Patients

Clinical Trial/Study

Studies Show Effect of Prasugrel vs. Clopidogrel on Readmissions, Initial Hospitalization Costs in ACS-PCI Patients
Low Clopidogrel Responsiveness Predicts Stent Thrombosis, Heart Attack
TRILOGY ACS Shows Prasugrel Not Superior to Clopidogrel in Medically Managed Non-STEMI Patients Without Revascularization
Daiichi Sankyo/Lilly Respond to Antiplatelet Clinical Alert
New Analysis Shows Prasugrel Cost-Effective Compared with Clopidogrel

Pharmaceuticals

Studies Show Effect of Prasugrel vs. Clopidogrel on Readmissions, Initial Hospitalization Costs in ACS-PCI Patients
Low Clopidogrel Responsiveness Predicts Stent Thrombosis, Heart Attack
New Data and Recent Advances in Antiplatelet Agents
Prasugrel Significantly Reduces Cardiovascular Events Over Clopidogrel
Prasugrel Added to Updated ACCF/AHA Guidelines for ACS-PCI Patients
Switching PCI Patients to Prasugrel from Clopidogrel Reduces Max Platelet Aggregation
Daiichi Sankyo/Lilly Respond to Antiplatelet Clinical Alert
New Analysis Shows Prasugrel Cost-Effective Compared with Clopidogrel
FDA Clears Effient to Reduce Thrombotic Cardiovascular Events in Patients after PCI
EFFIENT Receives European Approval for Prevention of Heart Attack in Patients Undergoing PCI
Plavix Rival Prasugrel Moves to Phase III Trial

Platelet Function Monitors

New Data and Recent Advances in Antiplatelet Agents

PET Accessories

Siemens PETNET Signs Agreement to Manufacture, Distribute Lilly’s PET Imaging Agent

Molecular Imaging

Siemens PETNET Signs Agreement to Manufacture, Distribute Lilly’s PET Imaging Agent

Nuclear Imaging

Siemens PETNET Signs Agreement to Manufacture, Distribute Lilly’s PET Imaging Agent

Stents

New Analysis Shows Prasugrel Cost-Effective Compared with Clopidogrel
FDA Clears Effient to Reduce Thrombotic Cardiovascular Events in Patients after PCI